Are angiotensin ii receptor blockers more efficacious than placebo in heart failure? implications of elite-2

This publication has 13 references indexed in Scilit:

• Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II
  The Lancet, 2000
• Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart Failure
  Circulation, 1999
• Angiotensin-converting enzyme-independent contraction to angiotensin I in human resistance arteries.
  Circulation, 1999
• Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: Rationale, design, and baseline characteristics of patients in the losartan heart failure survival study-ELITE II
  Journal of Cardiac Failure, 1999
• Rationale and design of the valsartan heart failure trial: A large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure
  Journal of Cardiac Failure, 1999
• Equivalence Trials
  New England Journal of Medicine, 1997
• Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
  Published by Elsevier ,1997
• Trials to assess equivalence: the importance of rigorous methods
  BMJ, 1996
• Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure
  New England Journal of Medicine, 1991
• Beta blockade during and after myocardial infarction: An overview of the randomized trials
  Progress in Cardiovascular Diseases, 1985